BARD1 INKS CANCER VACCINE COLLABORATION WITH IRH

- New research collaboration to evaluate BARD1 cancer vaccine
- Global Cancer Vaccine market valued at US$3.5B

Perth, Australia, 5 April 2017: Australian biotechnology company BARD1 Life Sciences Limited (ASX:BD1) (BARD1 LSL or the Company) today announced that it had entered into a collaboration with the Institute for Respiratory Health (IRH) to evaluate a BARD1 cancer vaccine for the prevention and/or treatment of cancer in animal models.

The project will evaluate various BARD1 formulations across several fully characterised tumour cell lines to determine their effectiveness in preventing tumour growth or reducing tumour size in two industry-accepted tumour models in mice. Additionally, the project will determine the optimal dose and timing for vaccination, and other secondary outcomes. BARD1 LSL has the option to terminate or extend the project depending on various milestones and outcomes.

Dr Leearne Hinch, CEO of BARD1 LSL, commented: “This agreement gives us the opportunity to explore the therapeutic potential of our BARD1 Technology. We have already demonstrated the utility of this technology in the diagnostic area, but therapeutic applications offer a large upside potential and, if the animal studies demonstrate effectiveness, this collaboration will enable us to advance our therapeutic program towards preclinical development.”

The Institute for Respiratory Health, in Perth, Western Australia, is a collaborative respiratory research organisation focused on respiratory illnesses including cancers of the lung. This collaboration expands on previous research conducted by BARD1 LSL’s Chief Scientific Officer, Dr Irmgard Irminger-Finger in experimental models.

Professor Geoff Laurent, Director of the Institute for Respiratory Health added: “We believe the BARD1 Technology has much to offer in the field of therapeutic vaccines for lung cancer. This is precisely the kind of mutually beneficial research collaboration that, if successful, will expand the therapeutic options for cancer patients.”

The global cancer vaccine market was valued at US$3.5B in 2016.1 BARD1 therapeutics have the potential to provide safe, effective and targeted solutions for the prevention and/or treatment of multiple cancers.

ENDS -

FOR MORE INFORMATION PLEASE CONTACT:

Peter Gunzburg | Dr Leearne Hinch
Chairman | CEO
E peter@bard1.com | E leearne@bard1.com
M +61 400 414 416

ABOUT BARD1 LIFE SCIENCES LTD (BARD1 LSL)
BARD1 Life Sciences Ltd (ASX:BD1) is an Australian biotechnology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. Its lead product, the BARD1 Lung Cancer Test, is a blood test in development for early detection of lung cancer, utilising novel tumour markers and a proprietary algorithm. The company’s pipeline also includes the BARD1 Ovarian Cancer Test in development for early detection of ovarian cancer, and high-value diagnostic and therapeutic projects at research-stage for multiple cancers. BARD1 LSL is committed to transforming the early detection and prevention of cancer to help improve patients’ lives.

ABOUT THE INSTITUTE FOR RESPIRATORY HEALTH
The Institute for Respiratory Health is a collaborative respiratory research organisation. It aims to improve the life of everyone living with a respiratory condition by bringing together world class researchers and dedicated clinicians to investigate, diagnose, treat and prevent respiratory conditions. The Institute conducts and fosters innovative basic and clinical research and translates its work into improved treatments for people with respiratory conditions.

The Institute for Respiratory Health campaigns for an increased awareness and investment in respiratory education and research. It focuses on real people and its work gives hope for a better future to those with respiratory disease.

ABOUT THE BARD1 TECHNOLOGY PLATFORM
The proprietary BARD1 Technology includes BARD1 tumour markers, diagnostic assays and algorithms. BARD1 tumour markers have potential utility as 1) diagnostic biomarkers for the detection and monitoring of cancer, and 2) therapeutic targets for immunotherapies that inhibit abnormal BARD1 for the prevention or treatment of cancer. The BARD1 Technology has potential applications across multiple cancers including lung, breast, ovarian, prostate, and colorectal cancer.

BARD1 is both a gene and a protein that plays an important role in the normal cell cycle and tumour suppression. However, cancer cells express numerous abnormal BARD1 proteins that drive oncogenesis (cancer formation), and are correlated with cancer progression and poor prognosis. Abnormal BARD1 proteins are immunogenic and induce circulating BARD1 autoantibodies in the blood. These abnormal BARD1 proteins (tumour-associated antigens) and autoantibodies are tumour markers that can be found in the blood of people with various cancer types and stages from early to late.